Meningococcemia in a Boy with Dense Deposit Disease Receiving the C5 Complement Inhibitor Ravulizumab: A Case Report.

Q4 Nursing
Andrew J Gonedes, Alexandra Martinez, Allan M Greissman, Hanan Atia, Eric Boccio
{"title":"Meningococcemia in a Boy with Dense Deposit Disease Receiving the C5 Complement Inhibitor Ravulizumab: A Case Report.","authors":"Andrew J Gonedes, Alexandra Martinez, Allan M Greissman, Hanan Atia, Eric Boccio","doi":"10.5811/cpcem.52835","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dense deposit disease, also known as C3 glomerulopathy, is a rare renal disorder caused by abnormal complement deposition in the glomerular basement membrane. Patients often require long-term immunosuppressive therapy and, in some cases, complement inhibitors such as ravulizumab. While effective at limiting renal damage, complement blockade significantly increases susceptibility to invasive infections from encapsulated bacteria, particularly Neisseria meningitidis. Despite immunization and antimicrobial prophylaxis, these patients remain incompletely protected. We describe a case of meningococcemia in a fully vaccinated adolescent with dense deposit disease on ravulizumab therapy.</p><p><strong>Case report: </strong>A 17-year-old male with a history of dense deposit disease on mycophenolate mofetil and ravulizumab presented to the pediatric emergency department with fever, vomiting, altered mental status, and a rapidly evolving petechial-purpuric rash. He was fully immunized with both meningococcal conjugate and serogroup B vaccines. Initial evaluation revealed fever, hypotension, and altered level of consciousness. Laboratory studies showed leukocytosis, elevated inflammatory markers, and blood cultures subsequently confirmed N. meningitidis. Empiric ceftriaxone and vancomycin were initiated, later narrowed to ceftriaxone. Supportive management included intravenous (IV) fluids, vasopressors, IV immunoglobulin, and dexamethasone. The patient demonstrated rapid improvement, with resolution of hemodynamic instability and normalization of kidney function. He was discharged on hospital day eight with prophylactic penicillin and close outpatient follow-up.</p><p><strong>Conclusion: </strong>This case underscores the risk associated with complement inhibition, even in fully vaccinated individuals. Clinicians must maintain high vigilance for meningococcal disease in immunocompromised patients and initiate early aggressive therapy to optimize outcomes.</p>","PeriodicalId":31975,"journal":{"name":"Clinical Practice and Cases in Emergency Medicine","volume":"10 2","pages":"174-177"},"PeriodicalIF":0.0000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135439/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Practice and Cases in Emergency Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5811/cpcem.52835","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Dense deposit disease, also known as C3 glomerulopathy, is a rare renal disorder caused by abnormal complement deposition in the glomerular basement membrane. Patients often require long-term immunosuppressive therapy and, in some cases, complement inhibitors such as ravulizumab. While effective at limiting renal damage, complement blockade significantly increases susceptibility to invasive infections from encapsulated bacteria, particularly Neisseria meningitidis. Despite immunization and antimicrobial prophylaxis, these patients remain incompletely protected. We describe a case of meningococcemia in a fully vaccinated adolescent with dense deposit disease on ravulizumab therapy.

Case report: A 17-year-old male with a history of dense deposit disease on mycophenolate mofetil and ravulizumab presented to the pediatric emergency department with fever, vomiting, altered mental status, and a rapidly evolving petechial-purpuric rash. He was fully immunized with both meningococcal conjugate and serogroup B vaccines. Initial evaluation revealed fever, hypotension, and altered level of consciousness. Laboratory studies showed leukocytosis, elevated inflammatory markers, and blood cultures subsequently confirmed N. meningitidis. Empiric ceftriaxone and vancomycin were initiated, later narrowed to ceftriaxone. Supportive management included intravenous (IV) fluids, vasopressors, IV immunoglobulin, and dexamethasone. The patient demonstrated rapid improvement, with resolution of hemodynamic instability and normalization of kidney function. He was discharged on hospital day eight with prophylactic penicillin and close outpatient follow-up.

Conclusion: This case underscores the risk associated with complement inhibition, even in fully vaccinated individuals. Clinicians must maintain high vigilance for meningococcal disease in immunocompromised patients and initiate early aggressive therapy to optimize outcomes.

接受C5补体抑制剂Ravulizumab治疗的致密沉积病男孩脑膜炎球菌血症1例报告
致密沉积病,又称C3肾小球病,是一种罕见的肾小球基底膜补体沉积异常引起的肾脏疾病。患者通常需要长期免疫抑制治疗,在某些情况下,需要补体抑制剂,如ravulizumab。补体阻断虽然能有效地限制肾脏损害,但会显著增加对包膜细菌侵袭性感染的易感性,尤其是脑膜炎奈瑟菌。尽管进行了免疫接种和抗菌素预防,但这些患者仍未得到完全保护。我们描述了一例脑膜炎球菌血症在一个充分接种疫苗的青少年密集沉积病的拉乌利珠单抗治疗。病例报告:一名17岁男性,有霉酚酸酯和拉乌利珠单抗致密沉积病史,以发烧、呕吐、精神状态改变和迅速发展的点紫癜疹就诊于儿科急诊科。他接种了脑膜炎球菌结合疫苗和血清B组疫苗。初步评估显示发烧、低血压和意识水平改变。实验室研究显示白细胞增多,炎症标志物升高,随后血培养证实脑膜炎奈瑟菌。经验头孢曲松和万古霉素开始,后来缩小到头孢曲松。支持性治疗包括静脉输液、血管加压药物、静脉注射免疫球蛋白和地塞米松。患者表现出快速的改善,血流动力学不稳定的解决和肾功能的正常化。患者于第8天出院,并给予预防性青霉素治疗和密切的门诊随访。结论:该病例强调了补体抑制相关的风险,即使在完全接种疫苗的个体中也是如此。临床医生必须对免疫功能低下患者的脑膜炎球菌病保持高度警惕,并开始早期积极治疗以优化结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
83
审稿时长
21 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书